Korean CHA Bio, U.S. ACT Ink $1.9 Billion Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech CHA Bio & Diostech has licensed a retinal pigment epithelium technology from U.S.-based Advanced Cell Technology. The agreement restricts CHA Bio's development and marketing of an end product to treat eye diseases to Korea only. The contract calls for milestone payments to ACT for as much as $1.9 billion, with ACT to have U.S. development rights. ACT expects to begin clinical trials later this year. The two companies have been engaged in other joint ventures for hemangioblast technology. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.